Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05669963

Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy

Conditions: Bacterial Vaginosis | Vaginal | Microbiology

Sex: Female
Ages: 20 Years – 37 Years
Phase: PHASE2, PHASE3
Enrollment: 66
Sponsor: Zagazig University

Location: Egypt

Summary

lactoferrin is believed to modulate immunity and help in prevention of recurrent bacterial vaginosis.In this study, the role of lactoferrin is assessed during third trimester of pregnancy.

Eligibility Criteria

Inclusion Criteria:Pregnant women of age group 20-37 years.Primigravida.28-40 week gestation.History of receurent bacterial vaginosis .Exclusion Criteria:Multiple gestations.Multiparity.Medical disorders as:Diabetes mellitus.Chronic hypertension.Endocrinal diseases.Autoimmune diseases.Renal diseases.Blood diseases.Allergy to lactoferrin .

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05669963). StuddyBuddy aggregates publicly available trial information.